# Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC

> **NCT06592664** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Lisata Therapeutics, Inc.**

## Conditions studied

- Pancreas Cancer
- Pancreatic Carcinoma
- Pancreas Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Unresectable Pancreatic Cancer
- Metastatic Pancreatic Cancer
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** certepetide
- **DRUG:** nab-paclitaxel
- **DRUG:** gemcitabine
- **DRUG:** placebo matching certepetide
- **DRUG:** certepetide
- **DRUG:** placebo matching certepetide
- **DRUG:** placebo matching certepetide

## Key facts

- **NCT ID:** NCT06592664
- **Lead sponsor:** Lisata Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2030-01
- **Primary completion:** 2035-01
- **Final completion:** 2040-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Management Decision
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06592664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06592664, "Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06592664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*